Fig. 5

Anti-HBV efficacy of tLNP/siHBV in rAAV-HBV1.3 mouse model. a Treatment and sampling schedule of the single-dose study. Mice were injected with rAAV-HBV1.3 (2.5 × 10¹⁰ viral genome (v.g.) per mice), 2 ~ 4 weeks later, the mice were grouped according to seral HBsAg levels, and treated with PBS, tLNP/siNC (1 mg/kg), tLNP/siHBV of different doses (0.1, 0.3, and 1 mg/kg), or given with Entecavir (ETV, 1 mg/kg) orally. b Mice were bled once weekly, and the seral levels of HBsAg, (c) HBeAg and (d) HBV DNA were monitored during the treatment course. Data were shown as means ± SDs (n = 8). e Treatment and sampling schedule of the multi-dose study. HBV-replicating mice model was obtained and grouped according to seral HBsAg levels. Mice were then treated with PBS, tLNP/siHBV at the doses of 1 mg/kg and 0.3 mg/kg, and at the frequency of once weekly (Q1W) or once bi-weekly (Q2W). f Mice were bled once weekly, and the seral levels of HBsAg, (g) HBeAg, and (h) HBV DNA during the treatment course were determined by commercial kits. i Body weights were monitored during the treatment course. Data were shown as means ± SDs (n = 8)